TC Biopharm (Holdings) Plc (TCBP)

Market Cap	3.70M
Revenue (ttm)	3.61M
Net Income (ttm)	-1.96M
Shares Out	9.36M
EPS (ttm)	-3.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	560,456
Open	0.395
Previous Close	0.368
Day's Range	0.370 - 0.400
52-Week Range	0.320 - 96.100
Beta	n/a
Analysts	Strong Buy
Price Target	70.00 (+17,621.52%)
Earnings Date	Dec 15, 2023

About TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 11, 2022
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: TCBP

Financial Performance

In 2022, TCBP's revenue was 3.84 million, an increase of 94.30% compared to the previous year's 1.98 million. Losses were -1.39 million, -89.76% less than in 2021.

Financial numbers in GBP

Analyst Forecast

According to one analyst, the rating for TCBP stock is "Strong Buy" and the 12-month stock price forecast is $70.0.

Price Target

$70.0

(17,621.52% upside)

Analyst Consensus: Strong Buy